Disc Surgery vs Stem Cells: What Does the Evidence Actually Show?

If you have been living with disc-related back pain for a year or more, you have probably been offered surgery, told to wait, or both. And somewhere in the research you have done since, stem cell therapy has come up — usually described in terms far more confident than the evidence supports, by clinics selling it or by forums dismissing it.

This article does neither. It sets out what the published trials actually found for both options, where the research is genuinely strong, where it is preliminary, and the specific situations where surgery is clearly the correct answer and cells are not.

The quick answer

For a herniated disc with leg pain (sciatica), surgery produces faster early relief, but the long-term trial data show non-operative patients catching up substantially by four years. For chronic discogenic low back pain without nerve compression, fusion surgery has modest and inconsistent results — which is precisely why interest in biological alternatives exists. Intradiscal mesenchymal stem cell (MSC) therapy has several completed randomized controlled trials, some reporting durable pain and function improvement over 36 months, alongside trials that did not separate from placebo. The overall evidence is best described as promising and incomplete, not established. And if you have progressive weakness, numbness in the saddle area, or loss of bladder or bowel control, none of this applies to you — that is a surgical emergency.

What each option actually is

Discectomy removes the fragment of disc material pressing on a nerve root. It is a decompression, not a repair — it addresses nerve compression and leaves the disc itself degenerated.

Fusion permanently joins two vertebrae to eliminate motion at a painful segment. It is a mechanical solution to a mechanical problem, and it transfers load to neighbouring levels.

Disc replacement substitutes an artificial disc, preserving motion at the treated level.

Intradiscal MSC therapy injects mesenchymal stromal cells directly into the nucleus of the disc, under image guidance. The intent is biological: the cells are thought to act mainly by releasing anti-inflammatory and trophic signals that alter the disc's environment, rather than by regrowing a new disc. That distinction matters, because "regrowing your disc" is a claim you will see marketed and it overstates what has been demonstrated in humans.

What the surgical evidence shows

The reference dataset for herniated discs is the Spine Patient Outcomes Research Trial (SPORT). Its four-year results, published in Spine, compared surgical with non-operative treatment for lumbar disc herniation. Surgical patients improved faster and reported greater benefit across primary outcomes — but the non-operative group also improved substantially, and the gap narrowed considerably over the follow-up period.[5] The practical reading is that discectomy reliably buys you faster relief from sciatica; it is less clear that it changes where you end up years later.

For chronic discogenic low back pain without nerve compression, the picture is weaker. A systematic review and meta-analysis of randomized controlled trials comparing lumbar fusion with non-operative management found the evidence for fusion's superiority to be limited and inconsistent.[6] This is the single most important context for the entire stem cell conversation: interest in biological approaches to discogenic pain exists largely because the surgical option in this specific population has never performed as well as patients assume.

Fusion also carries a structural trade-off. A systematic review with meta-analysis on adjacent segment degeneration and disease after lumbar fusion documents the load-transfer problem — eliminating motion at one level increases demand on the levels above and below.[7] This is not an argument against fusion, which remains the right operation for many people. It is an argument for not doing it earlier than necessary.

What the stem cell evidence shows

Unlike much of the regenerative field, intradiscal MSC therapy does have randomized controlled trials rather than only case series.

Noriega and colleagues randomized patients with degenerative disc disease to allogeneic bone marrow MSC injection or a sham-controlled comparator, publishing in Transplantation in 2017. The treated group showed improvement in pain and disability scores, with imaging changes reported in a subset.[1] The trial was small, which limits how far it can be generalized.

The largest body of evidence comes from allogeneic mesenchymal precursor cells. Amirdelfan and colleagues published a prospective randomized, placebo-controlled 36-month study of safety and efficacy in The Spine Journal in 2021, reporting durable improvement in pain and function in treated patients over three years.[2] A subsequent randomized, double-blind, concurrent-controlled 36-month study by Beall and colleagues, published in The Spine Journal in 2025, examined the same cell type with and without hyaluronic acid.[3]

Pulling this together, a 2026 systematic review and meta-analysis of randomized trials of intradiscal MSC therapy for degenerative disc disease in Asian Spine Journal assessed the pooled data.[4] The consistent finding across this literature is a favourable safety profile and signals of benefit in pain and function — alongside real heterogeneity between trials in cell type, dose, patient selection, and outcome measures, and trials that did not achieve their primary endpoints.

Where the research is genuinely weak

An honest reading requires naming the limitations, because they are substantial:

• No head-to-head trials. Surgery and cell therapy have never been randomized against each other for the same patients. Every comparison, including this one, is indirect.
• Small samples. Most intradiscal MSC trials enrol tens to low hundreds of patients, against surgical trials enrolling thousands.
• Heterogeneity. Cell source, dose, preparation method, and patient selection differ across trials, so pooled results should be read cautiously.
• Negative and null results exist. Not every trial has separated from placebo, and back pain is a condition with a notably strong placebo response — which is exactly why sham-controlled design matters.
• Follow-up is short. Thirty-six months is the longest robust follow-up. Surgical outcomes are tracked over decades.

Any clinic presenting this evidence base as settled is misrepresenting it. We have written a broader assessment of where the field stands in our guide to what MSC research actually shows in 2026.

Who may be a candidate

Based on the inclusion criteria used across the published trials, the patients most plausibly suited to intradiscal cell therapy tend to share these features:

• Chronic discogenic low back pain, generally six months or longer
• Failure of a genuine course of conservative care — physiotherapy, activity modification, medication
• Imaging showing moderate degeneration, with disc height substantially preserved
• Pain that correlates with the disc level seen on imaging
• No severe nerve compression, instability, or deformity requiring mechanical correction
• Realistic expectations, and understanding that this is not a guaranteed outcome

When this is not the right treatment for you

This therapy may not be right for you, and there are situations where it is clearly not.

Seek emergency surgical assessment — not an injection — if you have loss of bladder or bowel control, numbness in the groin or saddle area, or progressive weakness in a leg. These can indicate cauda equina syndrome or a significant neurological deficit, where delay causes permanent harm.

Cell therapy is also not appropriate where:

• The disc has collapsed. Severe height loss means there is little viable disc left to influence biologically. This is a structural problem needing a structural solution.
• There is significant instability, spondylolisthesis, or deformity. Cells do not stabilize a spine.
• Severe stenosis is causing neurological symptoms. Decompression is the treatment.
• Active infection, active malignancy, or pregnancy is present.
• Sciatica from a large extruded fragment is the dominant problem — that is a decompression question.

We decline patients on these grounds regularly, and would rather say so before you book travel. For a full picture of how we assess spinal cases and what treatment involves, see our back and spinal conditions page; our post on stem cells for herniated discs covers the herniation scenario specifically.

How to think about the decision

A few principles that hold regardless of which way you go:

Sequence matters. Cell therapy does not remove surgical options. Fusion largely does remove the option of preserving that segment. Where both are reasonable and there is no urgency, the less irreversible intervention first is a defensible order of operations — a judgement to make with your own spine surgeon, not a rule.

Match the treatment to the problem. Compression problems want decompression. Instability wants stabilization. Biological therapies are aimed at a disc that is degenerating but still structurally present. Most disappointment comes from applying one to the other.

Get your imaging read by someone with nothing to sell you. An MRI showing degeneration does not prove the disc is the source of your pain — degenerative changes are common in people with no symptoms at all.

Ask about non-response rates. Every genuine treatment has one. A clinic unwilling to tell you the percentage of patients who get no meaningful benefit is not giving you informed consent. The questions worth asking are set out in our guide to choosing a stem cell clinic, and Colombia's regulatory framework is explained in our INVIMA explainer.

The bottom line

Surgery has stronger and longer evidence, and for nerve compression it is often the right answer. For chronic discogenic pain without compression, the surgical evidence is weaker than most patients assume, and intradiscal cell therapy has a real but immature body of randomized evidence showing a good safety profile and signals of durable benefit in a subset of patients.

What no one can honestly tell you today is which will work better for you specifically, because that trial has not been run. What we can do is look at your imaging and history and tell you which category you fall into — including when the answer is that you need a surgeon rather than us.